Interferon-beta treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity

Area of Science:

• Pharmacogenetics
• Neuroimmunology
• Drug Metabolism

Background:

• Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• Interferon-beta (IFN-beta) is a common disease-modifying therapy for MS.
• Understanding drug-drug interactions is crucial for managing MS patients on multiple medications.

Purpose of the Study:

• To investigate the impact of interferon-beta (IFN-beta) treatment on the activity of key drug-metabolizing enzymes, specifically CYP2C19 and CYP2D6.
• To assess potential alterations in metabolic ratios for probe drugs used to determine CYP2C19 and CYP2D6 activity before and during IFN-beta therapy in MS patients.

Main Methods:

• Assessed CYP2C19 and CYP2D6 activity using mephenytoin and debrisoquine probe drugs, respectively.
• Measured urinary metabolic ratios (MR) for mephenytoin (S/R) and debrisoquine (debrisoquine/hydroxy-debrisoquine) in 10 MS patients.
• Performed genotyping for common CYP2C19 and CYP2D6 genetic variants (CYP2C19*2, *3; CYP2D6*3, *4, *5).

Main Results:

• No significant differences were observed in the (S)/(R) mephenytoin ratio or debrisoquine MR before and during IFN-beta treatment in extensive metabolizers (EM).
• Analysis showed no significant changes in enzyme activity regardless of the specific IFN-beta formulation used.
• Genotyping data were collected but not explicitly detailed in the results summary regarding their direct impact on the observed metabolic ratios.

Conclusions:

• Interferon-beta treatment does not appear to affect the metabolic activity of CYP2C19 or CYP2D6 in patients with multiple sclerosis.
• The findings suggest that substrates of CYP2C19 and CYP2D6 can be safely administered to MS patients undergoing IFN-beta therapy.
• No dose adjustments are likely necessary for medications metabolized by these enzymes when co-administered with IFN-beta.